# Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin

> **NCT07201545** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 58 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Bempedoic acid
- **DRUG:** Ezetimibe
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT07201545
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-10-07
- **Primary completion:** 2025-12-10
- **Final completion:** 2025-12-10
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07201545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07201545, "Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07201545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*